Company intelligence / Profile preview

Meridian Laboratories

Buffalo Grove, Illinois, United States

Ownership: Private
Development stage: Other

Overview

ML141 (docetaxel injectable, improved formulation) received U.S. FDA approval in 2022; proprietary PARP+ATR dual inhibitor is in development targeting prostate and potentially other cancers; improved cabazitaxel formulation is also reported in pipeline.

Therapeutic areas: Oncology
Modalities: Small moleculeImproved formulations
Industry: Biotech

Partnerships

Apobiologix (division of Apotex), for development/marketing of docetaxel improved formulation

Beyond the preview

Go deeper on Meridian Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meridian Laboratories.

Explore the full profile